Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform …

FPB Kroon, A Najm, A Alunno, JW Schoones… - Annals of the …, 2022 - ard.bmj.com
Objectives Perform a systematic literature review (SLR) on risk and prognosis of SARS-CoV-2
infection and vaccination against SARS-CoV-2 in patients with rheumatic and …

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non‐radiographic axial spondyloarthritis)

FPB Kroon, LRA Van Der Burg… - Cochrane Database …, 2015 - cochranelibrary.com
Background Axial spondyloarthritis (axSpA) comprises ankylosing spondylitis (radiographic
axSpA) and non‐radiographic (nr‐) axSpA and is associated with psoriasis, uveitis and …

Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of …

FPB Kroon, L Carmona, JW Schoones… - RMD open, 2018 - rmdopen.bmj.com
To update the evidence on efficacy and safety of non-pharmacological, pharmacological
and surgical interventions for hand osteoarthritis (OA), a systematic literature review was …

2018 update of the EULAR recommendations for the management of hand osteoarthritis

M Kloppenburg, FPB Kroon, FJ Blanco… - Annals of the …, 2019 - ard.bmj.com
Since publication of the European League Against Rheumatism (EULAR) recommendations
for management of hand osteoarthritis (OA) in 2007 new evidence has emerged. The aim …

EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November …

RBM Landewé, FPB Kroon, A Alunno, A Najm… - Annals of the …, 2022 - ard.bmj.com
The first EULAR provisional recommendations on the management of rheumatic and
musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome coronavirus …

Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial

…, D Elewaut, TWJ Huizinga, FPB Kroon… - Annals of the …, 2018 - ard.bmj.com
Objective Hand osteoarthritis is a prevalent disease with limited treatment options. Since
joint inflammation is often present, we investigated tumour necrosis factor (TNF) as treatment …

Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial

FPB Kroon, MC Kortekaas, A Boonen, S Böhringer… - The Lancet, 2019 - thelancet.com
Background Hand osteoarthritis is a prevalent joint condition that has a high burden of disease
and an unmet medical need for effective therapeutic options. Since local inflammation is …

[HTML][HTML] Intra-articular therapies in the treatment of hand osteoarthritis: a systematic literature review

FPB Kroon, R Rubio, JW Schoones, M Kloppenburg - Drugs & aging, 2016 - Springer
Background Local treatments to alleviate symptoms in hand osteoarthritis (OA) are preferred,
especially in elderly patients with comorbidities. Therefore, we have summarized the …

Nonsteroidal antiinflammatory drugs for axial spondyloarthritis: a Cochrane review

FPB Kroon, LRA Van Der Burg, S Ramiro… - The Journal of …, 2016 - jrheum.org
Objective. To determine the benefits and harms of nonsteroidal antiinflammatory drugs (NSAID)
in axial spondyloarthritis (axSpA). Methods. Systematic review using Cochrane …

Do comorbidities play a role in hand osteoarthritis disease burden? Data from the hand osteoarthritis in secondary care cohort

W Damman, R Liu, FPB Kroon, M Reijnierse… - The Journal of …, 2017 - jrheum.org
Objective. Because the association and its clinical relevance between comorbidities and
primary hand osteoarthritis (OA) disease burden is unclear, we studied this in patients with …